Adam Feuerstein, Elaine Chen, and Allison DeAngelis

BioTech

AbbVie’s stumble, Amgen’s tumble and more election fallout

Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C.

Adam Feuerstein, Elaine Chen, and Allison DeAngelis November 14, 2024

BioTech

Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions

Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory standards used

Adam Feuerstein, Elaine Chen, and Allison DeAngelis October 24, 2024

BioTech

Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides

What does the hiring of a well-known industry dealmaker mean for the future of BioMarin Pharmaceuticals? Can Eli Lilly’s blockbuster obesity medicine lower the risk

Adam Feuerstein, Elaine Chen, and Allison DeAngelis August 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Adam Feuerstein, Elaine Chen, and Allison DeAngelis

AbbVie’s stumble, Amgen’s tumble and more election fallout

Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions

Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe